Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hasmukh Jain

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Journal of Clinical Pathology|March 12, 2026
Acute myeloid leukaemia (AML) harbouring <i>KMT2A</i>-PTD: should it be considered as a myelodysplasia-related abnormality?Narasimhapriyan Kannan, Aarti Achrekar, Vishram Terse, et al.
Hemasphere|April 3, 2024
Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplantPrashant R Tembhare, Harshini Sriram, Twinkle Khanka, et al.
Nature Cancer|April 5, 2022
Outcomes of COVID-19 and risk factors in patients with cancerManju Sengar, Girish Chinnaswamy, Priya Ranganathan, et al.
Blood Cancer Journal|March 15, 2025
Outcomes and prognostic factors in patients with Burkitt lymphoma/leukemia in adolescents and adults: an experience from hematology cancer consortiumAkhil Rajendra, Manju Sengar, Anu Korula, et al.
JCO Global Oncology|February 20, 2026
Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AMLGojiri Mawalankar, Aarti Achrekar, Seema Biswas, et al.
Blood|December 5, 2025
Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL ConsortiumMark N Sorial, Luis Malpica, Carlos Sergio Chiattone, et al.
British Journal of Haematology|September 16, 2024
Impact of the COVID-19 pandemic on treatment of patients with acute myeloid leukaemia in IndiaChepsy Philip, Sushil Selvarajan, Lingaraj Nayak, et al.
The Lancet. Haematology|March 16, 2025
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 studyHasmukh Jain, Atharva Karulkar, Devanshi Kalra, et al.
Cancer Medicine|October 31, 2020
COVID-19 in cancer patients on active systemic therapy - Outcomes from LMIC scenario with an emphasis on need for active treatmentAnant Ramaswamy, Lingaraj Nayak, Nirmalya Roy Moulik, et al.
Annals of Hematology|July 8, 2024
Treatment challenges and outcomes of older patients with acute myeloid leukemia from IndiaSuvir Singh, Sharon Lionel, Hasmukh Jain, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Journal of Clinical Pathology|March 12, 2026
Acute myeloid leukaemia (AML) harbouring <i>KMT2A</i>-PTD: should it be considered as a myelodysplasia-related abnormality?Narasimhapriyan Kannan, Aarti Achrekar, Vishram Terse, et al.
Hemasphere|April 3, 2024
Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplantPrashant R Tembhare, Harshini Sriram, Twinkle Khanka, et al.
Nature Cancer|April 5, 2022
Outcomes of COVID-19 and risk factors in patients with cancerManju Sengar, Girish Chinnaswamy, Priya Ranganathan, et al.
Blood Cancer Journal|March 15, 2025
Outcomes and prognostic factors in patients with Burkitt lymphoma/leukemia in adolescents and adults: an experience from hematology cancer consortiumAkhil Rajendra, Manju Sengar, Anu Korula, et al.
JCO Global Oncology|February 20, 2026
Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AMLGojiri Mawalankar, Aarti Achrekar, Seema Biswas, et al.
Blood|December 5, 2025
Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL ConsortiumMark N Sorial, Luis Malpica, Carlos Sergio Chiattone, et al.
British Journal of Haematology|September 16, 2024
Impact of the COVID-19 pandemic on treatment of patients with acute myeloid leukaemia in IndiaChepsy Philip, Sushil Selvarajan, Lingaraj Nayak, et al.
The Lancet. Haematology|March 16, 2025
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 studyHasmukh Jain, Atharva Karulkar, Devanshi Kalra, et al.
Cancer Medicine|October 31, 2020
COVID-19 in cancer patients on active systemic therapy - Outcomes from LMIC scenario with an emphasis on need for active treatmentAnant Ramaswamy, Lingaraj Nayak, Nirmalya Roy Moulik, et al.
Annals of Hematology|July 8, 2024
Treatment challenges and outcomes of older patients with acute myeloid leukemia from IndiaSuvir Singh, Sharon Lionel, Hasmukh Jain, et al.
Pageof 8